These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16768128)

  • 1. [Natural history of Japanese patients with non-alcoholic fatty liver disease (NAFLD), especially non-alcoholic steatohepatitis (NASH) patients with hepatocellular carcinoma (HCC)].
    Yatsuji S; Hashimoto E
    Nihon Rinsho; 2006 Jun; 64(6):1173-9. PubMed ID: 16768128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic criteria for non-alcoholic steatohepatitis].
    Hashimoto E
    Nihon Rinsho; 2006 Jun; 64(6):1025-32. PubMed ID: 16768105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.
    Yatsuji S; Hashimoto E; Tobari M; Taniai M; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2009 Feb; 24(2):248-54. PubMed ID: 19032450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
    Cuadrado A; Orive A; García-Suárez C; Domínguez A; Fernández-Escalante JC; Crespo J; Pons-Romero F
    Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
    Berkan-Kawińska A; Piekarska A
    Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NASH and HCC.
    Page JM; Harrison SA
    Clin Liver Dis; 2009 Nov; 13(4):631-47. PubMed ID: 19818310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
    Starley BQ; Calcagno CJ; Harrison SA
    Hepatology; 2010 May; 51(5):1820-32. PubMed ID: 20432259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
    Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
    Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.